Monday, March 11, 2019 12:07:01 PM
Meirluc and Flipper44,
I don’t know. I saw that the patient was being treated in Dresden.
The medical center in Dresden was the first site to open in Germany, which was initiated in late May 2014.
Maybe the lady got an honest answer to her question from Prof. Dr. Dietmar Krex, senior neurosurgeon at the Department of Neurosurgery, University Hospital of Dresden, Germany, and Medical Advisor to NW Bio's Hospital Exemption program.
Maybe this is interesting to read:
Common European recommendations establish a framework for testing medicines of the future.
08 March 2019
The common European subgroup for complex clinical trials with trial subjects, which is headed by Denmark, has just published a set of recommendations for the development of personalised medicine.
The medicines agencies in the EU have just published a set of common recommendations on how to conduct complex clinical trials of personalised medicine. The recommendations have been published on the website of the common European Clinical Trials Facilitation and Coordination Group (CTFG).
The recommendations focus on ensuring a continuous assessment of the effects and side effects of investigational medicinal products, the safety of trial subjects and transparency of the data being used; they also define what may reasonably be considered a complex clinical trial and what should be considered as separate clinical trials.
Complex clinical trial
The recommendations have been prepared in recognition of the fact that the development of personalised medicine is gaining ground and clinical trials with trial subjects are becoming more and more complex. New medicines have traditionally been developed in relatively simple randomised trials in which the effect of a new treatment is tested against a standard treatment in a large group of patients. The development of personalised medicine usually takes place with fewer patients who are selected, for example, based on their specific DNA profile.
These complex trials with trial subjects offer the opportunity to develop new medicines that can be tailored to an individual patient with a specific genotype. The development of this type of medicines has made rapid progress in recent years – especially in the cancer area.
Need for common European guidelines.
The increased complexity of the trials may expose trial subjects to greater risks. Likewise, the quality of data can be deteriorated, and the trials could be difficult to comprehend. Consequently, common European guidelines have been needed to harmonise the conduct of trials while ensuring high-quality data and the safety of trial subjects.
The CTFG is formed by the network of the heads of the medicines agency in Europe known as the Heads of Medicines Agencies (HMA). The Danish Medicines Agency has coordinated the working group for complex clinical trials.
https://laegemiddelstyrelsen.dk/en/news/2019/common-european-recommendations-establish-a-framework-for-testing-medicines-of-the-future/
Clinical Trials Facilitation and Coordination Group CTFG.
Recommendation Paper on the Initiation and Conduct of Complex Clinical Trials.
12 February 2019
http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2019_02_CTFG_Recommendation_paper_on_Complex_Clinical_Trials.pdf
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM